redalpine Closes $250 Million RAC VIII Fund to Back European AI and Science Startups

redalpine has closed its latest early-stage venture fund, redalpine capital VIII (RAC VIII), at $250 million, giving the European investor fresh capital to back companies combining software with scientific advances. The oversubscribed fund will target around 20 companies across Europe, primarily leading Seed and Series A rounds with initial investments of $1 million to $15 million.

The close comes as the firm marks 20 years in business and takes its assets under management above $1.4 billion. Its first RAC VIII investments span robots that sense physical forces, AI tools for biological research, and systems that uncover relationships in complex datasets. Together, they show where redalpine sees opportunity as AI moves deeper into scientific and industrial workflows.

A $250 Million Fund for Software and Science

Founded in Zurich in 2006, redalpine has built a portfolio that includes Proxima Fusion, Mistral AI, N26, Basecamp Research, and microagi. The firm says half its investment team consists of trained scientists, including biologists, physicists, and engineers. That mix matters when evaluating a startup whose central challenge could involve robotic control, biological measurement, or a new computing architecture as much as software distribution.

“Twenty years ago, we started redalpine with the conviction that the most important companies would emerge where software and science meet,” said Dr. Michael Sidler, founding partner at redalpine. “That belief hasn’t changed. With RAC VIII, we’re excited to keep backing these founders early, before the opportunity is obvious.”

RAC VIII is an early-stage fund within a broader investment platform designed to support businesses from Seed through later stages. The $250 million represents the new fund’s capital commitments; the more than $1.4 billion figure covers the firm’s assets under management across its platform.

redalpine says it reviews more than 5,000 companies annually. Its planned portfolio of around 20 businesses leaves room for concentrated investments, with the stated $1 million to $15 million range describing initial checks rather than each company’s eventual total financing.

Robotics That Learn From Force and Touch

One of RAC VIII’s first investments is Enact Intelligence, which is developing force intelligence for robots. The technical premise is that seeing an object and understanding an instruction provide only part of what a machine needs to manipulate the physical world.

In its October portfolio update, redalpine describes Enact as feeding torque and touch information into a foundation model alongside vision and language. Those additional signals give a robot information about contact and physical interaction. For tasks involving dexterity, that could help a system adapt its actions as resistance or contact changes, rather than relying solely on a visual estimate.

The investment illustrates a broader challenge in physical AI: useful behavior depends on connecting perception to sensing and control. Enact’s approach seeks to make force awareness part of that learning process.

Virtual Biology Labs and Traceable Data Analysis

A second investment, Helical, is building a virtual AI laboratory for drug discovery. Its platform applies biological foundation models to research workflows, including target discovery, cell-state analysis, and patient stratification. Its Model Factory adapts and benchmarks models for particular biological questions, while its virtual lab supports computational experiments.

Helical also maintains an open-source framework for working with biological foundation models, including genomics and single-cell data. The practical opportunity is to make model-based investigation repeatable and accessible within a research workflow. Computational findings still need experimental validation; a virtual lab helps researchers prioritize and investigate hypotheses rather than establishing a treatment’s effectiveness by itself.

The third named investment, Arlequin AI, focuses on extracting patterns and relationships from large, fragmented datasets. Its HuDex platform presents applications ranging from financial-transaction analysis and due diligence to communications forensics and supply-chain investigation.

Arlequin describes its approach in terms of unsupervised and topological AI, emphasizing relationships across data and the ability to trace findings to supporting records. In high-stakes analysis, that traceability is important: users need to inspect the evidence behind a connection before acting on it. The company’s stated approach emphasizes understanding patterns in data, extending the fund’s AI exposure beyond generating text.

Institutional Backing and a Longer Investment Horizon

RAC VIII’s limited partners include Aviva Investors, Flexstone Partners, and KfW, alongside entrepreneurs, executives, and business owners. Their participation gives the fund a mix of institutional capital and investors with operating experience.

redalpine reports 12 portfolio-company exits since 2023. It also says companies backed by RAC VII, its previous early-stage fund that closed in 2024, have subsequently raised more than $1.1 billion in aggregate financing. Those figures describe portfolio activity and follow-on fundraising; they do not establish the new fund’s investment returns.

For redalpine, the new vehicle extends a strategy that connects technical expertise with early capital and support as companies grow. For Europe’s AI ecosystem, the initial portfolio offers a concrete view of that strategy: investing in the sensing, biological models, and analytical architectures that turn advances in AI into capabilities for specific industries.